HannaH phase III randomised study: association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.
| dc.contributor.author | Jackisch, Christian | |
| dc.contributor.author | Hegg, Roberto | |
| dc.contributor.author | Stroyakovskiy, Daniil | |
| dc.contributor.author | Jin-Seok Ahn | |
| dc.contributor.author | Melichar, Bohuslav | |
| dc.contributor.author | Shin-Cheh Chen | |
| dc.contributor.author | Sung-Bae Kim | |
| dc.contributor.author | Lichinitser, Mikhail | |
| dc.contributor.author | Starosławska, Elzbieta | |
| dc.contributor.author | Kunz, Georg | |
| dc.contributor.author | Falcón, Silvia | |
| dc.contributor.author | Shou-Tung Chen | |
| dc.contributor.author | Crepelle-Fléchais, Aulde | |
| dc.contributor.author | Heinzmann, Dominik | |
| dc.contributor.author | Shing, Mona | |
| dc.contributor.author | Pivot, Xavier | |
| dc.date.accessioned | 2019-04-10T16:46:39Z | |
| dc.date.available | 2019-04-10T16:46:39Z | |
| dc.date.issued | 2016-05 | |
| dc.identifier.citation | European Journal of Cancer | es_PE |
| dc.identifier.issn | 0959-8049 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12959/202 | |
| dc.description.abstract | Desde el estudio HannaH fase 3 aleatorizado, se reporta la asociación entre la respuesta total patológica completa y la supervivencia libre de eventos en el cáncer de mama HER2-positivo temprano, tratado con trastuzumab adyuvante-neoadyuvante de dosis fija, con más eficacia y seguridad a largo plazo. | es_PE |
| dc.format | application/pdf | es_PE |
| dc.language.iso | eng | es_PE |
| dc.publisher | Seguro Social de Salud (EsSalud) | es_PE |
| dc.rights | info:eu-repo/semantics/openAccess | es_PE |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | es_PE |
| dc.source | Seguro Social de Salud (EsSalud) | es_PE |
| dc.source | Repositorio Institucional EsSalud | es_PE |
| dc.subject | Oncología | es_PE |
| dc.subject | Farmacología y Farmacia | es_PE |
| dc.subject | Neoplasias de la mama | es_PE |
| dc.subject | Trastuzumab | es_PE |
| dc.title | HannaH phase III randomised study: association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up. | es_PE |
| dc.type | info:eu-repo/semantics/article | es_PE |
| dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.05.00 | es_PE |
| dc.publisher.country | PE | es_PE |
Files in this item
This item appears in the following Collection(s)
-
Artículos científicos [933]
Artículos de revistas escritos por profesionales de la salud de EsSalud
Except where otherwise noted, this item's license is described as info:eu-repo/semantics/openAccess
